[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-433940-105":59,"doc-detail-433940-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","early-dose-escalation-of-tirzepatide-after-switching-from-semaglutide-in-type-2-diabetes-mellitus-brief-report","Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus - Brief Report","","Tirzepatide shows stronger effects than semaglutide for glycemic control and body-weight reduction in type 2 diabetes mellitus (T2DM), yet the optimal dose after switching from 1.0 mg semaglutide is unclear. This retrospective study enrolled 15 T2DM patients with inadequate weight loss who started tirzepatide at 2.5 mg and escalated to 7.5 mg (n=10) or 10 mg (n=5). Over 3 months, the 10 mg group significantly reduced HbA1c and showed a weight-loss trend, with no significant changes in the 7.5 mg group.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/early-dose-escalation-of-tirzepatide-after-switching-from-semaglutide-in-type-2-diabetes-mellitus-brief-report/433940/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/early-dose-escalation-of-tirzepatide-after-switching-from-semaglutide-in-type-2-diabetes-mellitus-brief-report/433940.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why was dose selection after switching from semaglutide to tirzepatide uncertain?","Question",{"text":112,"@type":113},"The study states that the optimal tirzepatide dose following a switch from 1.0 mg semaglutide remains unclear despite tirzepatide’s stronger efficacy overall.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients assigned to the tirzepatide dose groups?",{"text":117,"@type":113},"Patients who switched to tirzepatide due to inadequate weight loss were started at 2.5 mg, then escalated to 7.5 mg (n=10) or 10 mg (n=5), with group classification based on the maintenance dose.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main outcomes over the 3-month follow-up?",{"text":121,"@type":113},"The primary endpoints were changes in body weight and HbA1c from baseline to 3 months. The 10 mg group significantly lowered HbA1c, while the 7.5 mg group showed no significant changes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},433940,1790718577,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":52,"preview_page_count":4},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Brief Report  \nEndocrinol Metab 2025;40:1012-1015 [https://doi.org/10.3803/EnM.2025.2420](https://doi.org/10.3803/EnM.2025.2420)[ ](https://doi.org/10.3803/EnM.2025.2420)[pISSN 2093-596X](pISSN 2093-596X) · eISSN 2093-5978  \nEarly Dose Escalation ofTirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus  \nNoboru Kurinami1,2,3, *, Masafumi Takada1, *, Seigo Sugiyama1,4, Akira Yoshida1, Kunio Hieshima1, Tomoko Suzuki1, Fumio Miyamoto1, Keizo Kajiwara1, Katsunori Jinnouchi1, Kenji Ashida2, Masatoshi Nomura2, Hideaki Jinnouchi1,5  \n1Diabetes Care Center, Jinnouchi Hospital, Kumamoto; 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume; 3Kurinami Clinic, Kanzaki; 4Division of Cardiovascular Medicine, Diabetes Care Center, Jinnouchi Hospital, Kumamoto; 5Division of Preventive Cardiology, Department of Cardiovascular Medicine, Kumamoto University Hospital, Kumamoto, Japan  \nTirzepatide has demonstrated greater efficacy than semaglutide in improving glycemic control and reducing body weight in patients with type 2 diabetes mellitus (T2DM). However, the optimal tirzepatide dose following a switch from 1.0 mg ofsemaglutide remains unclear. This retrospective study included 15 T2DM patients who switched to tirzepatide due to inadequate weight loss. All patients started tirzepatide at 2.5 mg, with escalation to either 7.5 mg (n = 10) or 10 mg (n = 5). Changes in glycated hemoglobin (HbA1c) and body weight were assessed over a 3-month period. The 10 mg group experienced a significant reduction in HbA1c (−0.7%±0.3%, P \u003C0.01) and a non-significant trend toward weight loss (−6.6±5.4 kg, P = 0.07) . In contrast, no significant changes were observed in the 7.5 mg group. There were no statistically significant differences between groups. Since 10 mg oftirzepatide significantly improved glycemic control after switching from 1.0 mg of semaglutide, early escalation to 10 mg may be beneficial for patients who respond inadequately to semaglutide.  \n\n| Keywords: Tirzepatide; Semaglutide; Diabetes mellitus, type 2; Body weight reduction; Dose escalation |  |\n| --- | --- |\n| INTRODUCTION\u003Cbr>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the management of type 2 diabetes mellitus (T2DM) due to their dual effects on glycemic control and body weight. Among these agents, tirzepatide has shown particularly strong weight-reducing properties [1]. In clinical practice, switching from semaglutide to tirzepatide has become increasingly common, especially in patients with suboptimal weight loss, highlighting the need for optimal dosing strategies. Tirzepatide is | typically initiated at 2.5 mg and titrated stepwise to higher doses depending on tolerability. However, the most appropriate dose for patients transitioning from high-dose semaglutide (1.0 mg) remains uncertain. This study aimed to evaluate the effects of different tirzepatide doses (7.5 mg vs. 10 mg) on weight reduction inpatients who switched from 1.0 mg ofsemaglutide.\u003Cbr>METHODS\u003Cbr>This retrospective observational study included patients with |\n| Received: 18 April 2025, Revised: 16 May 2025, Accepted: 9 June 2025\u003Cbr>Corresponding author: Hideaki Jinnouchi\u003Cbr>Diabetes Care Center, Jinnouchi Hospital, 6-2-3 Kuhonji, Chuo-ku, Kumamoto 862-0976, Japan\u003Cbr>Tel: +81-96-363-0011, Fax: +81-96-364-2654, [E-mail:](E-mail: hideaki@jinnouchi.or.jp)[ hideaki@jinnouchi.or.jp](E-mail: hideaki@jinnouchi.or.jp)[ ](E-mail: hideaki@jinnouchi.or.jp)*These authors contributed equally to this work. | Copyright © 2025 Korean Endocrine Society\u003Cbr>This is an Open Access article distributed under the terms of\u003Cbr>the Creative Commons Attribution Non-Commercial License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.\u003Cbr>|\n\n1012 [www","cbCaildZQ3PcMlCu","https://ap.wps.com/l/cbCaildZQ3PcMlCu","pdf",407052,"English","# Introduction\n# Methods","[{\"question\":\"Why was dose selection after switching from semaglutide to tirzepatide uncertain?\",\"answer\":\"The study states that the optimal tirzepatide dose following a switch from 1.0 mg semaglutide remains unclear despite tirzepatide’s stronger efficacy overall.\"},{\"question\":\"How were patients assigned to the tirzepatide dose groups?\",\"answer\":\"Patients who switched to tirzepatide due to inadequate weight loss were started at 2.5 mg, then escalated to 7.5 mg (n=10) or 10 mg (n=5), with group classification based on the maintenance dose.\"},{\"question\":\"What were the main outcomes over the 3-month follow-up?\",\"answer\":\"The primary endpoints were changes in body weight and HbA1c from baseline to 3 months. The 10 mg group significantly lowered HbA1c, while the 7.5 mg group showed no significant changes.\"}]","Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus - Brief Report | PDF",1790666333]